Am­gen touts two can­cer study wins with DLL3, Lumakras amid sec­ond-quar­ter earn­ings up­date

Two can­cer drugs suc­ceed­ed in mid- or late-stage clin­i­cal stud­ies, Am­gen said Thurs­day in its sec­ond-quar­ter earn­ings an­nounce­ment.

“Mo­men­tum is build­ing in the pipeline,” Am­gen CFO Pe­ter Grif­fith told End­points News, adding the biotech plans to dis­cuss both datasets with reg­u­la­tors, call­ing a study for the DLL3-tar­get­ing drug tar­latam­ab “po­ten­tial­ly reg­is­tra­tional.”

In a Phase II small cell lung can­cer study, tar­latam­ab showed a durable re­sponse rate that “sub­stan­tial­ly ex­ceeds what was pre­vi­ous­ly re­port­ed in the Phase I study,” the $123 bil­lion drug­mak­ing gi­ant said in its midyear up­date. But spe­cif­ic da­ta were sparse in Thurs­day’s re­lease; Am­gen said it will present more de­tailed re­sults at an up­com­ing med­ical con­fer­ence.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER